Skip to main content
. 2009 Feb 17;100(4):737–746. doi: 10.1111/j.1349-7006.2009.01083.x

Figure 2.

Figure 2

Dehydroxymethylepoxyquinomicin (DHMEQ) reduced viability of primary effusion lymphoma (PEL) cells. PEL cell lines and K562 cells were treated with indicated concentrations of DHMEQ for 72 h (A) or were treated for the indicated hours with 10 µg/mL of DHMEQ (B). K562 cell line, without NF‐κB activation, was used as a control. The cell viability was determined by WST‐8 (Dojindo). The mean percentages of triplicate experiments compared with untreated cells are shown with standard deviation (SD).